m+Medelevator.RU
← Поиск публикаций
Journal of molecular biology · 2026

Microscale Thermophoresis for Thermodynamic Analysis: A Proof-of-Concept Study on LIMK Inhibitors.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Chartier Solweig, Claude Bérengère, Nasreddine Rouba, Soule Pierre, Launay Alexandra, Rapeto Mélanie, Villalonga-Rosso Elodie, Vallée Béatrice, Sebban Muriel, Coadou Gaël, Nehmé Reine

Аннотация

LIMK1 and LIMK2, key regulators of cytoskeleton dynamics, are notoriously difficult to produce and purify in quantities sufficient for conventional biochemical studies, yet they are promising therapeutic targets due to their role in actin filament turnover and microtubule remodeling. To overcome these limitations, we developed a microscale thermophoresis (MST)-based thermodynamic assay as a proof-of-concept to study LIMK-inhibitor interactions directly in HEK293 cell lysates overexpressing fluorescent miRFP670-LIMK fusion proteins, completely bypassing protein purification. Dissociation constants (Kd) were measured across multiple temperatures and analyzed by van't Hoff plots, yielding highly linear correlations (r2 = 0.958-0.999). LIMK1 and its kinase domain (Kin1) showed comparable binding behavior to TH-257 and LX7101 (ΔG37°C = -10.3 ± 0.4 kcal mol-1), whereas LIMK2 interactions were significantly weaker (ΔG37°C lower by ∼1.5 kcal mol-1). Binding was enthalpy-driven, with entropy opposing complex formation, highlighting opportunities for rational optimization of inhibitors. This work establishes MST as a user-friendly, purification-free platform for deriving protein-ligand thermodynamics directly in cell lysates, providing a versatile proof-of-concept approach for studying challenging targets and guiding the development of therapeutically relevant inhibitors.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты